As a result of the low oral bioavailability of ganciclovir, a prodrug was developed to improve
the bioavailability of ganciclovir. This study was designed to investigate the fasting, single …

Objective Ganciclovir is commonly used in the treatment of cytomegalovirus (CMV) disease
in patients who are immunocompromised and for the prevention of CMV disease in solid …

Background Valganciclovir is the oral prodrug of ganciclovir. The pharmacokinetics of
valganciclovir in patients with renal impairment is not known. Furthermore, it is not known …

Valganciclovir (Valcyte™) is an orally administered prodrug of the standard anti-
cytomegalovirus (CMV) drug ganciclovir. Valganciclovir is as effective as intravenous …

Oral ganciclovir has recently been approved for use in long-term maintenance therapy in the
treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. Although oral …

Abstract A phase I/II study evaluated the pharmacokinetics, tolerability, and antiviral activity
of oral ganciclovir in persons infected with human immunodeficiency virus (HIV). Oral …

A protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS)
method has been developed and validated for the simultaneous determination of …

Immunocompromised hosts are at increased risk of cytomegalovirus (CMV) infection and
serious CMV disease. CMV infection is an important cause of morbidity among patients …

The pharmacokinetics of an orally administered valine ester of ganciclovir (GCV),
valganciclovir (VGC), were studied. These were compared to the pharmacokinetics of oral …

The aim of this study was to determine whether oral ganciclovir interacted
pharmacokinetically with zidovudine (AZT), didanosine (ddl), or probenecid. A multicenter …